[Splenic tuberculosis during psoriasis treatment with infliximab].
Psoriasis is a chronic inflammatory disease affecting the skin and occasionally the joints. The biological agents have been engineered to target a specific step in the inflammatory cascade that leads to psoriasis, including tumor necrosis factor, which has a central role in the host defense against Mycobacterium tuberculosis. This is a case report about a psoriatic patient who presented splenic tuberculosis during treatment with infliximab.
Hospital das Clínicas de Pernambuco, Universidade Federal de Pernambuco, Recife, PE, Brasil. glefortaleza@hotmail.com
Gleyce Tavares de Melo
GT
Fortaleza
Maria de Fátima de Medeiros
Mde F
Brito
Josemir Belo dos
JB
Santos
Ana Roberta
AR
Figueiredo
Perla
P
Gomes
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003879:Dermatologic Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D014400:Tuberculosis, Splenic / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab